Table 1. Baseline population characteristics.
| Wild type (n=258) | mKRAS (n=196) | mEGFR (n=27) | P-value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 171 (66%) | 132 (67%) | 12 (44%) | 0.06 |
| Female | 87 (34%) | 64 (33%) | 15 (56%) | |
| Mean agea | 63.8±11.25 | 64.4±11.28 | 64.7±13.56 | 0.93 |
| Charlson comorbidity index | ||||
| 0 | 32 (13%) | 18 (9%) | 3 (11%) | 0.69 |
| 1 | 94 (36%) | 74 (38%) | 13 (48%) | |
| 2 | 67 (26%) | 58 (29%) | 4 (15%) | |
| 3 | 65 (25%) | 46 (23%) | 7 (26%) | |
| pT | ||||
| 1 | 61 (24%) | 42 (22%) | 4 (15%) | |
| 2 | 104 (41%) | 101 (51%) | 6 (22%) | 0.004 |
| 3 | 77 (30%) | 44 (23%) | 16 (53%) | |
| 4 | 16 (6%) | 9 (5%) | 1 (4%) | |
| pN | ||||
| N+ | 94 (37%) | 164 (84%) | 15 (56%) | <0.0001 |
| N0 | 164 (63%) | 32 (16%) | 12 (44%) | |
| Angio-invasion | ||||
| Yes | 75 (29%) | 121 (62%) | 11 (41%) | <0.0001 |
| No | 183 (71%) | 75 (38%) | 16 (59%) | |
| Smoking habit | ||||
| Never smoked | 23 (9%) | 22 (11%) | 23 (85%) | <0.0001 |
| Former smoker | 115 (44%) | 80 (41%) | 3 (11%) | |
| Active smoker | 120 (47%) | 94 (48%) | 1 (4%) | |
| Neo-adjuvant treatment | ||||
| Yes | 107 (41%) | 62 (32%) | 17 (63%) | 0.003 |
| No | 151 (59%) | 134 (68%) | 10 (37%) | |
| Type of neo-adjuvant treatment | ||||
| Chemotherapy | 76 (72%) | 54 (85%) | 9 (53%) | <0.0001 |
| Radio-chemotherapy | 30 (28%) | 9 (15%) | 8 (47%) | |
| Adjuvant treatment | ||||
| Yes | 98 (38%) | 165 (84%) | 16 (59%) | <0.0001 |
| No | 160 (62%) | 31 (16%) | 11 (41%) | |
| Type of adjuvant treatment | ||||
| Chemotherapy | 74 (76%) | 151 (91%) | 15 (94%) | <0.0001 |
| Radiotherapy | 4 (4%) | 1 (1%) | 1 (6%) | |
| Radio-chemotherapy | 20 (20%) | 13 (8%) | 0 | |
| Lymph node ratio | ||||
| <1/3 | 86 (91%) | 76 (47%) | 11 (73%) | <0.0001 |
| ⩾1/3 | 8 (9%) | 88 (53%) | 4 (27%) | |
| Skip-N2 | ||||
| Yes | 0 | 4 (13%) | 3 (50%) | 0.07 |
| No | 0 | 27 (87%) | 3 (50%) | |
| Microscopic N | ||||
| Yes | 0 | 15 (9%) | 8 (53%) | <0.0001 |
| No | 94 (100%) | 149 (91%) | 7 (47%) | |
| Number of N2 stations | ||||
| 1 | 42 (79%) | 20 (65%) | 6 (100%) | 0.11 |
| 2 | 11 (21%) | 11 (35%) | 0 | |
| Resection margins | ||||
| R0 | 252 (98%) | 192 (99%) | 26 (96%) | 0.47 |
| R1 | 6 (2%) | 2 (1%) | 1 (4%) |
Abbreviations: mEGFR=epidermal growth factor receptor mutations; mKRAS=V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue mutations.
a
Data are given as mean±s.d. Bold values were used to indicate significant variables.